Trials / Completed
CompletedNCT02714881
Lipids, Inflammation, and CV Risk in RA
Lipids, Inflammation, and Cardiovascular Risk in Rheumatoid Arthritis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 74 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 35 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study was to examine the relationship between inflammation, lipids, and cardiovascular risk in rheumatoid arthritis. The central hypothesis is that reducing inflammation will reduce cardiovascular risk as measured by coronary flow reserve. Additionally, we hypothesized that lipid levels may have a weaker correlation with CV risk compared to the general population.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Certolizumab |
Timeline
- Start date
- 2016-10-17
- Primary completion
- 2020-12-14
- Completion
- 2022-12-21
- First posted
- 2016-03-22
- Last updated
- 2026-01-21
- Results posted
- 2026-01-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02714881. Inclusion in this directory is not an endorsement.